Patrick Jean-Philippe Selected Research

Therapeutics

1/2022	Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
1/2021	Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.
1/2021	Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women.
1/2021	Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus.
11/2019	Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile.
10/2019	Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
1/2018	Prevalence of Asymptomatic Parasitemia and Gametocytemia in HIV-Infected Children on Differing Antiretroviral Therapy.
1/2017	HIV birth testing and linkage to care for HIV-infected infants.
7/2011	Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrick Jean-Philippe Research Topics

Disease

7	Tuberculosis (Tuberculoses) 07/2023 - 07/2011
6	HIV Infections (HIV Infection) 01/2021 - 08/2010
4	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 01/2017
3	Meningococcal Infections 09/2017 - 01/2012
2	Viremia 01/2023 - 01/2021
2	Neutropenia 01/2021 - 11/2008
2	Infections 11/2019 - 07/2011
2	Body Weight (Weight, Body) 12/2011 - 07/2011
2	Disease Progression 11/2008 - 02/2002
1	Weight Gain 01/2024
1	Congenital Abnormalities (Deformity) 01/2023
1	Perinatal Death 01/2021
1	Clinical Deterioration 10/2020
1	Liver Failure 10/2019
1	Coinfection 01/2019
1	Malaria 01/2018
1	Parasitemia 01/2018
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 06/2015
1	Anemia 11/2008
1	Exanthema (Rash) 11/2007
1	Chickenpox 11/2007
1	Pneumonia (Pneumonitis) 11/2007
1	Mitochondrial Diseases (Mitochondrial Disease) 05/2007

Drug/Important Bio-Agent (IBA)

4	Nevirapine (Viramune)FDA Link 01/2021 - 10/2010
3	efavirenz (Sustiva)FDA Link 01/2022 - 01/2017
3	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 01/2022 - 01/2017
3	Isoniazid (Ftivazide)FDA LinkGeneric 01/2021 - 07/2011
3	NucleosidesIBA 01/2018 - 05/2007
3	Reverse Transcriptase InhibitorsIBA 01/2018 - 05/2007
3	Conjugate VaccinesIBA 09/2017 - 08/2010
2	RacivirIBA 01/2024 - 12/2011
2	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2021
2	Ritonavir (Norvir)FDA Link 10/2020 - 01/2018
2	Lopinavir FDA Link 10/2020 - 01/2018
1	Rifampin (Rifampicin)FDA LinkGeneric 07/2023
1	Broadly Neutralizing AntibodiesIBA 01/2023
1	CreatinineIBA 01/2023
1	Transaminases (Aminotransferases)IBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	dolutegravirIBA 01/2021
1	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 01/2021
1	FumaratesIBA 01/2021
1	Emtricitabine (Emtriva)FDA Link 01/2021
1	tenofovir alafenamideIBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	butyl phosphorotrithioate (DEF)IBA 10/2020
1	HIV Protease InhibitorsIBA 01/2018
1	Fc Receptors (Fc Receptor)IBA 06/2013
1	Immunoglobulin G (IgG)IBA 06/2013
1	Mannose (D-Mannose)IBA 06/2013
1	Interleukin-10 (Interleukin 10)IBA 06/2013
1	Toll-Like Receptor 2IBA 06/2013
1	BCG Vaccine FDA Link 07/2011
1	Stavudine (Zerit)FDA LinkGeneric 11/2008
1	Zidovudine (Retrovir)FDA LinkGeneric 11/2008
1	Chickenpox Vaccine (Vaccine, Varicella)IBA 11/2007
1	VaccinesIBA 11/2007

Therapy/Procedure

9	Therapeutics 01/2022 - 07/2011
1	Art Therapy 01/2021
1	Duration of Therapy 06/2015
1	Secondary Prevention 11/2008
1	Highly Active Antiretroviral Therapy (HAART) 02/2002